Build the Right Stakeholder Plan for a Payer Review

A payer review can fall apart in the first few minutes, not because your data is weak, but because the wrong person answers the wrong question. You walk in without a clear map of who owns which topic, and you end up watching a sales colleague guess at trial methodology or a medical colleague hint at a contract term nobody authorized. The payer notices. The fix is not a better slide deck. It is a stakeholder plan built before the meeting even gets scheduled.

Why This Meeting Goes Sideways

Payer reviews almost always mix two different conversations into one hour. One is economic, covering price, formulary placement, rebates, and utilization management. The other is scientific, covering trial design, endpoints, comparative evidence, and safety data. Most manufacturer teams do not staff these as separate tracks. They send whoever is available and hope the conversation stays inside each person's lane.

It rarely does. A payer pharmacist asks a commercial lead about statistical power. A payer medical director asks a sales representative to confirm a rebate structure. Neither person should answer, but silence feels worse than a guess, so someone improvises. The payer either gets a wrong answer or an answer that sounds like a commitment. Both outcomes cost you credibility on the next call, and both are avoidable with fifteen minutes of planning.

Prepare Before You Send the Invite

Do the planning on a short call with your payer contact, before you build the agenda or pick attendees. Ask four things. First, what decision or review step does this meeting actually support. A formulary committee vote needs different preparation than a routine quarterly check in. Second, which questions require clinical evidence and which relate to access operations such as prior authorization criteria or provider communication. Third, how much time you actually have, since a thirty minute virtual slot cannot cover five topics with the depth each one deserves. Fourth, who from the payer side will be in the room, since a pharmacist and a medical director bring different questions than a contracting manager.

Once you have those answers, match each topic to one internal owner who has the authority to speak on it. Do not position a sales colleague to answer a clinical question just because that person happens to be free that afternoon. Do not ask a medical science liaison to confirm pricing or contract terms either. Those two boundaries protect the payer relationship and protect your own colleagues from being asked to speak past their role.

What to Say on the Call

Preparation calls go wrong when you accept the payer's framing without checking it first. Suppose the payer contact asks whether sales can answer the clinical questions, since scheduling a medical science liaison takes an extra week. That is the moment to redirect, not comply.

You might say, "I want this discussion to be accurate as well as useful, so let's separate the clinical questions from the access questions first. Once we know which is which, I can bring in the right scientific resource for anything related to trial data or comparative evidence, and I will cover the access and operational questions myself. What are the two or three topics your team cares most about for this review."

The payer contact answers that the top priorities are evidence methodology for the pivotal trial and how provider offices will be notified about an upcoming utilization management change. You respond, "Good, that gives me what I need. I will bring our medical science liaison to walk through methodology, and I will personally handle the provider communication plan since that is an access question. If anything comes up that touches a pending coverage decision, I will follow up in writing rather than answer on the spot." That last point matters. When a scientific question edges into a signal about a coverage decision that has not been finalized, apply the same discipline described in Communicate Carefully About a Pending Coverage Changewhere saying less on the call and following up in writing protects everyone.

The contact agrees to the split and asks for a written agenda ahead of time. You send one that lists each topic, the question behind it, and the name of the person answering it.

Mistakes That Undermine the Plan

A few habits sink this process even when you mean well. Treating availability as qualification is the most common one, where the person who happens to be on the call becomes the person who answers, regardless of whether the topic is theirs to own. Letting a scientific colleague respond to a pricing or contracting question is just as damaging, since that answer can sound like a commitment even when it was offered as a passing comment.

Skipping the written agenda is another mistake. Without a document that names each topic and its owner, attendees improvise once the payer changes the order of questions, which happens often. Confirming roles verbally on the morning of the meeting is not the same as sending a calendar invitation with topics and owners spelled out days in advance.

Do not let a scientific colleague or sales colleague field a question outside their scope just to keep the conversation moving. A short pause to say the right person will follow up in writing costs far less credibility than a guess that turns out wrong. The same rule applies in other payer settings, and Build a PBM Meeting Agenda for Scientific Questions walks through matching every scientific question to a named owner before a PBM meeting starts.

Practice the Split Before the Real Call

This conversation is hard to get right the first time you try it live, since the payer will not wait while you sort out who answers what. Rehearse it instead. Run a roleplay where the counterpart plays a payer contact who mixes clinical and economic questions and offers a short meeting slot, then practice separating the topics out loud the way you would on the real call.

Score the rehearsal on three things. Did you ask for the decision or review step behind the meeting instead of assuming you already knew. Did you separate clinical questions from access questions before agreeing to a format. Did you name an owner for each topic rather than leaving it open. A manager reviewing the recording should also check whether you resisted the pressure to answer outside your own scope just to fill a silence.

DealSpeak's practice conversations built for this industry let you run this scenario against an AI payer contact who pushes back the way a real one does, then score your answers against these same criteria. Find more scenarios like this one among the Pharmaceuticals practice conversationsincluding ones that build on the same stakeholder mapping skill for other payer and PBM settings.

Close

A stakeholder plan is not a formality. It is the difference between a payer meeting that builds trust and one that creates a new problem to clean up afterward. Map the topics, name the owners, and send the agenda before the call starts, and the meeting runs itself.